Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Approved to Launch PCSK9 Inhibitor in China for High-Cholesterol

publication date: Aug 21, 2023

Suzhou Innovent Biologics was approved to launch its anti-PCSK9 monoclonal antibody in China to treat adult patients with primary hypercholesterolemia and mixed dyslipidemia. The first domestic PCSK9 inhibitor approved in China, Sintbilo® (tafolecimab injection) is Innovent's first approved drug for a cardiovascular indication and its tenth marketed product. Sintbilo® is an lgG2 fully human monoclonal antibody that binds to PCSK9. It reduces LDL-C levels by inhibiting PCSK9-mediated low-density lipoprotein receptor (LDLR) endocytosis, which raises the clearance of LDL-C and lowers LDL-C levels in the blood. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital